Sionna Therapeutics SION 深 滬
等待開盤 08-21 09:30:00 美东时间
5.52
-0.730
-11.68%
華盛通- 最 高6.2726
- 今 開6.27
- 成交量 174.95万股
- 最 低 5.51
- 昨 收 6.25
- 總市值 2.50亿
- 52周最高 54.97
- 市盈率 靜 --
- 換手率 3.87%
- 52周最低 4.01
- 委 比 91.20%
- 總股本 4521.24万
- 歷史最高 54.97
- 量 比 0.57
- 振 幅 12.20%
- 歷史最低 4.01
- 每 手 1
- 風險率 8.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 云计算概念狂飙！NEBIUS飙升34%，CoreWeave升超19%；QNT劲升28%
云计算概念狂飙！NEBIUS飙升34%，AI云收入暴增514%；CoreWeave升超19%，积压订单破千亿美元；QNT劲升28%，携手甲骨文布局量子云+财报指引超预期>>
08-13 16:27
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Guggenheim Downgrades Sionna Therapeutics to Neutral
Guggenheim analyst Yatin Suneja downgrades Sionna Therapeutics (NASDAQ:SION) from Buy to Neutral.
08-11 22:17
美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%
周一，福泰制药(VRTX.US)早盘涨近7%，创历史新高;而竞争对手Sionna Therapeutics(SION.US)暴跌超90%，创记录新低。消息面上...
08-10 23:39
Sionna Reports Mixed Trial Results, Refocuses CF Pipeline
Sionna Therapeutics, Inc. ( ($SION) ) has shared an announcement. On August 10,...
08-10 19:48
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Guggenheim Maintains Buy on Sionna Therapeutics, Raises Price Target to $60
Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the price target from $50 to $60.
08-08 01:11
Sionna Therapeutics Q2 EPS $(0.66) Misses $(0.65) Estimate
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 60.98 percent decrease over losses of $(0.41) per share from the same period last year.
08-06 19:39
Sionna Therapeutics Reports Second Quarter 2026 Financial Results
Sionna Therapeutics reported Q2 2026 financial results with $268.3M in cash, supporting operations into 2028. The company advanced its clinical programs, with Phase 2a and Phase 1 trials on track for summer 2026 data. R&D and G&A expenses increased due to pipeline development and growth initiatives. The company remains focused on advancing NBD1 stabilizers to potentially transform cystic fibrosis treatment.
08-06 11:00
